These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. A transplantable human medullary thyroid carcinoma as a model for RET tyrosine kinase-driven tumorigenesis. Johanson V; Ahlman H; Bernhardt P; Jansson S; Kölby L; Persson F; Stenman G; Swärd C; Wängberg B; Stridsberg M; Nilsson O Endocr Relat Cancer; 2007 Jun; 14(2):433-44. PubMed ID: 17639056 [TBL] [Abstract][Full Text] [Related]
23. Cabozantinib and vandetanib for unresectable locally advanced or metastatic medullary thyroid cancer: a systematic review and economic model. Tappenden P; Carroll C; Hamilton J; Kaltenthaler E; Wong R; Wadsley J; Moss L; Balasubramanian S Health Technol Assess; 2019 Feb; 23(8):1-144. PubMed ID: 30821231 [TBL] [Abstract][Full Text] [Related]
24. Management of Medullary Thyroid Cancer. Viola D; Elisei R Endocrinol Metab Clin North Am; 2019 Mar; 48(1):285-301. PubMed ID: 30717909 [TBL] [Abstract][Full Text] [Related]
25. Medullary thyroid cancer: a promising model for targeted therapy. Torino F; Paragliola RM; Barnabei A; Corsello SM Curr Mol Med; 2010 Oct; 10(7):608-25. PubMed ID: 20712590 [TBL] [Abstract][Full Text] [Related]
26. Management of Advanced Medullary Thyroid Carcinoma: Current Systemic Therapy Options. Jara MA Crit Rev Oncog; 2024; 29(3):83-90. PubMed ID: 38683155 [TBL] [Abstract][Full Text] [Related]
27. RET fusion as a novel driver of medullary thyroid carcinoma. Grubbs EG; Ng PK; Bui J; Busaidy NL; Chen K; Lee JE; Lu X; Lu H; Meric-Bernstam F; Mills GB; Palmer G; Perrier ND; Scott KL; Shaw KR; Waguespack SG; Williams MD; Yelensky R; Cote GJ J Clin Endocrinol Metab; 2015 Mar; 100(3):788-93. PubMed ID: 25546157 [TBL] [Abstract][Full Text] [Related]
28. Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study. Subbiah V; Hu MI; Wirth LJ; Schuler M; Mansfield AS; Curigliano G; Brose MS; Zhu VW; Leboulleux S; Bowles DW; Baik CS; Adkins D; Keam B; Matos I; Garralda E; Gainor JF; Lopes G; Lin CC; Godbert Y; Sarker D; Miller SG; Clifford C; Zhang H; Turner CD; Taylor MH Lancet Diabetes Endocrinol; 2021 Aug; 9(8):491-501. PubMed ID: 34118198 [TBL] [Abstract][Full Text] [Related]
29. Genetics of medullary thyroid cancer: An overview. Accardo G; Conzo G; Esposito D; Gambardella C; Mazzella M; Castaldo F; Di Donna C; Polistena A; Avenia N; Colantuoni V; Giugliano D; Pasquali D Int J Surg; 2017 May; 41 Suppl 1():S2-S6. PubMed ID: 28506408 [TBL] [Abstract][Full Text] [Related]
30. Vandetanib in a Child Affected by Neurofibromatosis Type 1 and Medullary Thyroid Carcinoma with Both Demir Gündoğan B; Sağcan F; Tuğ Bozdoğan S; Balcı Y; Tuncel Daloğlu F; Çağlar Çıtak E J Clin Res Pediatr Endocrinol; 2021 Aug; 13(3):342-346. PubMed ID: 32702947 [TBL] [Abstract][Full Text] [Related]
31. [Vandetanib, in the management of patients with locally advanced or metastatic medullary thyroid carcinomas]. Chougnet CN; Schlumberger M; Leboulleux S; Baudin E Bull Cancer; 2014 Sep; 101(9):891-5. PubMed ID: 25296193 [TBL] [Abstract][Full Text] [Related]
32. Targeting RET receptor tyrosine kinase activation in cancer. Phay JE; Shah MH Clin Cancer Res; 2010 Dec; 16(24):5936-41. PubMed ID: 20930041 [TBL] [Abstract][Full Text] [Related]
34. Clinical utility of genetic diagnosis for sporadic and hereditary medullary thyroid carcinoma. Elisei R; Bottici V; Cappagli V; Ramone T; Tacito A; Ciampi R; Romei C Ann Endocrinol (Paris); 2019 Jun; 80(3):187-190. PubMed ID: 31053251 [TBL] [Abstract][Full Text] [Related]
35. Real-World Efficacy and Safety of Cabozantinib and Vandetanib in Advanced Medullary Thyroid Cancer. Koehler VF; Adam P; Frank-Raue K; Raue F; Berg E; Hoster E; Allelein S; Schott M; Kroiss M; Spitzweg C Thyroid; 2021 Mar; 31(3):459-469. PubMed ID: 32781914 [No Abstract] [Full Text] [Related]
36. Qi XP; Jin BY; Li PF; Wang S; Zhao YH; Cao ZL; Yu XH; Cheng J; Fang XD; Zhao JQ Thyroid; 2019 Oct; 29(10):1447-1456. PubMed ID: 31364476 [No Abstract] [Full Text] [Related]
37. Vandetanib and the management of advanced medullary thyroid cancer. Campbell MJ; Seib CD; Gosnell J Curr Opin Oncol; 2013 Jan; 25(1):39-43. PubMed ID: 23202050 [TBL] [Abstract][Full Text] [Related]
38. Phase I/II Trial of Vandetanib and Bortezomib in Adults with Locally Advanced or Metastatic Medullary Thyroid Cancer. Del Rivero J; Edgerly M; Ward J; Madan RA; Balasubramaniam S; Fojo T; Gramza AW Oncologist; 2019 Jan; 24(1):16-e14. PubMed ID: 30297385 [TBL] [Abstract][Full Text] [Related]
39. Mortalin (GRP75/HSPA9) upregulation promotes survival and proliferation of medullary thyroid carcinoma cells. Starenki D; Hong SK; Lloyd RV; Park JI Oncogene; 2015 Aug; 34(35):4624-34. PubMed ID: 25435367 [TBL] [Abstract][Full Text] [Related]
40. Cabozantinib: a MET, RET, and VEGFR2 tyrosine kinase inhibitor. Grüllich C Recent Results Cancer Res; 2014; 201():207-14. PubMed ID: 24756794 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]